Neoleukin Therapeutics Book Value 2011-2026 | NLTX

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Neoleukin Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
265 M	310 M	186 M	98.6 M	143 M	191 M	142 M	72.7 M	98.9 M	145 M	108 M	36.1 M	10.8 M	-51.1 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
310 M	-51.1 M	125 M

Quarterly Book Value Neoleukin Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
266 M	273 M	292 M	310 M	137 M	155 M	-	186 M	75.2 M	79.6 M	81.4 M	94.3 M	106 M	117 M	130 M	143 M	155 M	167 M	179 M	191 M	191 M	191 M	191 M	142 M	142 M	142 M	142 M	72.7 M	72.7 M	72.7 M	72.7 M	98.9 M	98.9 M	98.9 M	98.9 M	145 M	145 M	145 M	145 M	108 M	108 M	108 M	108 M	36.1 M	36.1 M	36.1 M	36.1 M	8.17 M	8.17 M	8.17 M	8.17 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
310 M	8.17 M	123 M

Book Value of other stocks in the Drug manufacturers industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	17 M	-	7.5 %	$ 6.35 M	USA
Alimera Sciences ALIM	46.2 M	-	-	$ 142 M	USA
Aerie Pharmaceuticals AERI	-17.3 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	-16.3 M	-	10.11 %	$ 58.2 M	USA
Adamis Pharmaceuticals Corporation ADMP	-651 K	-	0.86 %	$ 117 M	USA
Eagle Pharmaceuticals EGRX	234 M	-	-39.89 %	$ 27.7 M	USA
Aurora Cannabis ACB	609 M	$ 3.43	3.31 %	$ 86.3 M	Canada
Catalent CTLT	3.6 B	-	-	$ 11.5 B	USA
Athenex ATNX	-24.2 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	73.8 M	-	-	$ 2.06 B	France
Pacira BioSciences PCRX	778 M	$ 23.16	-0.19 %	$ 1.07 B	USA
Cronos Group CRON	1.71 B	$ 2.64	2.13 %	$ 1.34 B	Canada
DURECT Corporation DRRX	45.2 M	-	-	$ 50.1 M	USA
Emergent BioSolutions EBS	649 M	$ 8.36	4.3 %	$ 428 M	USA
Endo International plc ENDP	5.14 B	-	-	$ 28.9 M	Irlanda
Perrigo Company plc PRGO	2.94 B	$ 9.84	2.07 %	$ 1.36 B	USA
Evoke Pharma EVOK	-2.58 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	1.46 B	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	314 M	-	2.45 %	$ 38.1 M	Canada
Cumberland Pharmaceuticals CPIX	22.5 M	$ 3.03	-3.19 %	$ 42.6 M	USA
Rockwell Medical RMTI	21.3 M	$ 1.08	4.37 %	$ 25.2 M	USA
Bausch Health Companies BHC	-82 M	$ 5.2	4.0 %	$ 1.9 B	Canada
PetIQ PETQ	868 M	-	1.64 %	$ 400 M	USA
Solid Biosciences SLDB	180 M	$ 7.1	6.26 %	$ 621 M	USA
OptiNose OPTN	-86.6 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	51.7 M	-	-27.8 %	$ 2.56 M	USA
Sundial Growers SNDL	1.1 B	$ 1.4	1.82 %	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	4.41 M	$ 2.34	-	$ 2.9 M	USA
ProPhase Labs PRPH	63.6 M	-	-	$ 5.07 M	USA
Evolus EOLS	-23.1 M	$ 4.44	0.23 %	$ 286 M	USA
Radius Health RDUS	-252 M	-	-	$ 1.42 B	USA
Tilray TLRY	3.33 B	$ 7.02	5.45 %	$ 4.34 B	Canada
Relmada Therapeutics RLMD	86.5 M	$ 6.43	5.41 %	$ 254 M	USA
OrganiGram Holdings OGI	306 M	$ 1.39	3.84 %	$ 402 M	Canada
SCYNEXIS SCYX	49.4 M	$ 0.92	2.51 %	$ 45.9 M	USA
Jupiter Wellness JUPW	-2.17 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	7.75 M	$ 0.59	3.79 %	$ 10.3 M	China
Veru VERU	32.3 M	$ 2.3	0.44 %	$ 310 M	USA
Lannett Company LCI	-251 M	-	1.15 %	$ 7.11 M	USA
Harrow Health HROW	52.1 M	$ 36.09	2.53 %	$ 1.33 B	USA
Viatris VTRS	21.1 B	$ 13.59	1.72 %	$ 16.3 B	USA
Organogenesis Holdings ORGO	385 M	$ 2.49	3.31 %	$ 328 M	USA
Canopy Growth Corporation CGC	487 M	$ 1.0	4.19 %	$ 108 M	Canada
cbdMD YCBD	1.96 M	$ 0.79	2.82 %	$ 3.41 M	USA
Assertio Holdings ASRT	94 M	$ 16.81	1.82 %	$ 108 M	USA
TherapeuticsMD TXMD	29.3 M	$ 2.28	-0.44 %	$ 23.8 M	USA
Recro Pharma REPH	58.7 M	-	-4.76 %	$ 65.3 M	USA
Tricida TCDA	218 K	-	-	$ 3.25 M	USA
Zynerba Pharmaceuticals ZYNE	46.2 M	-	-	$ 55.5 M	USA